Relevant Current and Past Publications

from Aarvik Co-founders

  • Exploration of the antibody–drug conjugate clinical landscape.

    H Maecker, V Jonnalagadda, S Bhakta, V Jammalamadaka, JR Junutula Mabs 15 (1), 2229101, 2023

  • Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies.

    Shane Miersch, Nitin Sharma, Reza Saberianfar, Chao Chen, Francesca Caccuri, Alberto Zani, Arnaldo Caruso, James Brett Case, Michael S. Diamond, Gaya K. Amarasinghe, Giuseppe Novelli, Sachdev S. Sidhu.(2022) Cell Reports 39, 110905. DOI: 10.1016.

  • In situ antibody phage display yields optimal inhibitors of integrin α11/β.

    Eugenio Gallo, Abdellali Kelil, Peter E. Bayliss, Ajitha Jeganathan, Olga Egorova, Lynda Ploder, Jarret A. Adams, Patricia Giblin & Sachdev S. Sidhu.
    (2020) mAbs, Vol 12, No. 1, e1717265.

  • A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced antitumor properties.

    Zvezdan Pavlovic, Jarrett J. Adams, Levi L. Blazer, Amandeep K. Gakhal, Nick Jarvik, Zachary Steinhart, Mélanie Robitaille, Keith Mascall, James Pan, Stephane Angers, Jason Moffat & Sachdev S. Sidhu.
    (2019) mAbs, Vol 10, No. 8, 1157-1167.

  • Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice.

    Yuyong Tao, Monika Mis, Levi Blazer, Mart Ustav Jnr, Zachary Steinhart, Rony Chidiac, Elli Kubarakos, Siobhan O’Brien, Xiaomei Wang, Nick Jarvik, Nish Patel, Jarrett Adams, Jason Moffat, Stephane Angers, Sachdev S. Sidhu.
    (2019) eLife, 8, e46134.

  • CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.

    Ying-Ping Jiang, Bob Y. Liu, Quan Zheng, Swapna Panuganti, Ruoying Chen, Jianyu Zhu, Madhavi Mishra, Jianqing Huang, Trang Dao-Pick, Sharmili Roy, XiaoXian Zhao, Jeffrey Lin, Gautam Banik, Eric D. Hsi, Ramkumar Mandalam, Jagath R. Junutula.
    (2018) Blood Adv., Vol 2 No 14, 1738-1749.

  • Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody–Drug Conjugate Payload.

    Sean W. Smith, Vasu Jammalamadaka, Dmitry Borkin, Jianyu Zhu, Sylvia J. Degrado, Jennifer Lu, Jianqing Huang, Ying-Ping Jiang, Nareshkumar Jain, and Jagath R. Junutula.
    (2018) ACS Med. Chem. Lett, 2018, 9, 1, 56–60.

  • An anti-GDNF family receptor alpha 1 (GFRA1 antibody–drug conjugate for the treatment of hormone receptor–positive breast cancer.

    Bhakta, S., Crocker, L.M., Chen, Y., Hazen, M., Schutten, M.M., Li, D., Kuijl, C., Ohri, R., Zhong, F., Poon, K.A., Go, M.A.T., Cheng, E., Piskol, R., Firestein, R., Fourie-O'Donohue, A., Kozak, K.R., Raab, H., Hongo, J.-A., Sampath, D., Dennis, M.S., Scheller, R.H., Polakis, P., Junutula, J.R.
    (2018) Molecular Cancer Therapeutics, 17 (3), pp. 638-649.

  • Structure-Directed and Tailored Diversity Synthetic Antibody Libraries Yield Novel Anti-EGFR Antagonists.

    Shane Miersch, Bharathikumar Vellalore Maruthachalam, C. Ronald Geyer, and Sachdev S. Sidhu.
    (2017) ACS Chemical Biology. DOI: 10.1021.

  • Site-specific antibody drug conjugates for cancer therapy.

    Panowski, S., Bhakta, S., Raab, H., Polakis, P., Junutula, J.R.
    (2014) mAbs, 6 (1), pp. 34-45.

  • CDR-H3 Diversity Is Not Required for Antigen Recognition by Synthetic Antibodies.

    Helena Persson, Wei Ye, Amy Wernimont, Jarrett J. Adams, Akiko Koide, Shohei Koide, Robert Lam and Sachdev S. Sidhu.
    (2013) J. Mol. Bio. 425, 803-811.

  • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

    Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K.L., Tien, J., Yu, S.-F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O.M., Scales, S.J., McDonald, P.J., Hass, P.E., Eigenbrot, C., Nguyen, T., Solis, W.A., Fuji, R.N., Flagella, K.M., Patel, D., Spencer, S.D., Khawli, L.A., Ebens, A., Wong, W.L., Vandlen, R., Kaur, S., Sliwkowski, M.X., Scheller, R.H., Polakis, P., Junutula, J.R.
    (2012) Nature Biotechnology, 30 (2), pp. 184-189.

  • Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

    Junutula, J.R., Flagella, K.M., Graham, R.A., Parsons, K.L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D.L., Li, G., Mai, E., Phillips, G.D.L., Hiraragi, H., Fuji, R.N., Tibbitts, J., Vandlen, R., Spencer, S.D., Scheller, R.H., Polakis, P., Sliwkowski, M.X.
    (2010) Clinical Cancer Research, 16 (19), pp. 4769-4778.

  • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

    Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S., Lu, Y., Meng, Y.G., Ng, C., Yang, J., Lee, C.C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S.D., Lee Wong, W., Lowman, H.B., Vandlen, R., Sliwkowski, M.X., Scheller, R.H., Polakis, P., Mallet, W.
    (2008) Nature Biotechnology, 26 (8), pp. 925-932.